Literature DB >> 17762398

Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals.

Jackie Yao Liu1, Kevin Qu, Anthony D Sferruzza, Richard A Bender.   

Abstract

The hepatic isoform 1A1 of uridine diphosphate glucuronosyltransferase is responsible for glucuronidation and detoxification of SN-38, the active metabolite of irinotecan. The presence of an additional TA repeat in the TATA sequence of the UGT1A1 promoter leads to a significant decrease in SN-38 glucuronidation. Patients with the UGT1A1 (TA)7 allele are more likely to experience severe neutropenia and diarrhea following irinotecan chemotherapy. We assessed the distribution of the UGT1A1 (TA)n polymorphism in healthy male and female US residents of European and Asian descent. We used a fluorescent polymerase chain reaction-based assay to detect UGT1A1 (TA)n polymorphisms in 138 healthy volunteers (56 Caucasians, 37 Chinese, 37 Filipino and eight Japanese) between the ages of 18 and 65 years. The chi-test was used to assess between-group differences in the distribution of UGT1A1 (TA)n genotypes. The UGT1A1 (TA)6/6 genotype was significantly more common in Asians than in Caucasians (76 vs. 46%), whereas the (TA)6/7 (39 vs. 20%) and (TA)7/7 (13 vs. 5%) genotypes were more common in Caucasians than in Asians. Genotype distributions did not differ significantly between men and women in either group. The UGT1A1 (TA)5/5 genotype was detected in one Caucasian woman. In conclusion, consistent with previous reports, the UGT1A1 (TA)7/7 genotype was significantly more common in Caucasians than in Asians. UGT1A1 (TA)n/n genotype distribution did not vary with sex in individuals of European or Asian descent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17762398     DOI: 10.1097/CAD.0b013e32803a46fe

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  19 in total

1.  Geographic difference in advanced gastric cancer prevalence and chemotherapy treatment results: could it really be an independent prognostic factor?

Authors:  Junichi Sakamoto; Koji Oba
Journal:  Gastric Cancer       Date:  2012-07       Impact factor: 7.370

Review 2.  Axitinib plasma pharmacokinetics and ethnic differences.

Authors:  Ying Chen; Akiyuki Suzuki; Michael A Tortorici; May Garrett; Robert R LaBadie; Yoshiko Umeyama; Yazdi K Pithavala
Journal:  Invest New Drugs       Date:  2015-02-08       Impact factor: 3.850

3.  Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group.

Authors:  Valerie Cristina; Jestinah Mahachie; Murielle Mauer; Thierry Buclin; Eric Van Cutsem; Arnaud Roth; Anna D Wagner
Journal:  JAMA Oncol       Date:  2018-07-01       Impact factor: 31.777

4.  Population pharmacokinetic analysis of axitinib in healthy volunteers.

Authors:  May Garrett; Bill Poland; Meghan Brennan; Brian Hee; Yazdi K Pithavala; Michael A Amantea
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

5.  Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects.

Authors:  Jung-Woo Bae; Chang-Ik Choi; Jin-Hee Lee; Choon-Gon Jang; Myeon-Woo Chung; Seok-Yong Lee
Journal:  Eur J Clin Pharmacol       Date:  2010-09-24       Impact factor: 2.953

Review 6.  Clinical pharmacology of axitinib.

Authors:  Ying Chen; Michael A Tortorici; May Garrett; Brian Hee; Karen J Klamerus; Yazdi K Pithavala
Journal:  Clin Pharmacokinet       Date:  2013-09       Impact factor: 6.447

Review 7.  Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.

Authors:  J M Campbell; M D Stephenson; E Bateman; M D J Peters; D M Keefe; J M Bowen
Journal:  Pharmacogenomics J       Date:  2016-08-09       Impact factor: 3.550

8.  Prevalence of topoisomerase I genetic mutations and UGT1A1 polymorphisms associated with irinotecan in individuals of Asian descent.

Authors:  Tomoya Fukui; Hisashi Mitsufuji; Masaru Kubota; Hidenori Inaoka; Minoru Hirose; Keiichi Iwabuchi; Noriyuki Masuda; Hirosuke Kobayashi
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

9.  Genetic polymorphisms in the TATA box and upstream phenobarbital-responsive enhancer module of the UGT1A1 promoter have combined effects on UDP-glucuronosyltransferase 1A1 transcription mediated by constitutive androstane receptor, pregnane X receptor, or glucocorticoid receptor in human liver.

Authors:  Ye Li; David Buckley; Shuang Wang; Curtis D Klaassen; Xiao-bo Zhong
Journal:  Drug Metab Dispos       Date:  2009-06-18       Impact factor: 3.922

10.  Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study.

Authors:  Masatoshi Kudo; Yoon-Koo Kang; Joong-Won Park; Shukui Qin; Yoshitaka Inaba; Eric Assenat; Yoshiko Umeyama; Maria José Lechuga; Olga Valota; Yosuke Fujii; Jean-Francois Martini; J Andrew Williams; Shuntaro Obi
Journal:  Liver Cancer       Date:  2017-12-08       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.